Kolkata News Today

Axial Spondyloarthritis (axSpA) Market to Exhibit Moderate Growth Rate till 2030 | Key Companies includes – FunPep, UCB Biopharma, Mycenax, Kinevant, Qyuns, Izana, Clover Biopharmaceuticals and Others

 Breaking News
  • No posts were found

Axial Spondyloarthritis (axSpA) Market to Exhibit Moderate Growth Rate till 2030 | Key Companies includes – FunPep, UCB Biopharma, Mycenax, Kinevant, Qyuns, Izana, Clover Biopharmaceuticals and Others

October 08
04:00 2021
Axial Spondyloarthritis (axSpA) Market to Exhibit Moderate Growth Rate till 2030 | Key Companies includes - FunPep, UCB Biopharma, Mycenax, Kinevant, Qyuns, Izana, Clover Biopharmaceuticals and Others
Delveinsight Business Research LLP
DelveInsight’s “Axial Spondyloarthritis (axSpA) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Axial Spondyloarthritis (axSpA) Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Axial Spondyloarthritis (axSpA) market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Axial Spondyloarthritis (axSpA) Market


Axial Spondyloarthritis (axSpA): An Overview

Axial spondyloarthritis (axSpA) is an umbrella term inflammatory arthritis type that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS).

Up to 6% of people with chronic back pain will ultimately receive a diagnosis of axial spondyloarthritis. However, the disease often takes as long as 10 years to be diagnosed—a delay that can hugely impact the quality of life and lead to disability, missed time at work, and increased healthcare costs. 

Axial Spondyloarthritis (axSpA) Market Key Facts

  • It is observed that around 5.5 million Americans have Axial Spondyloarthritis (axSpA). It generally starts in people during their teens or in their twenties, or maybe in their thirties.

  • Males and females are equally affected with Axial Spondyloarthritis (axSpA) in the 7MM.

  • Typically, axSpA affects the younger SpA patient population, with an average age of symptom onset of 28 years. AxSpA consists of 2 subsets of patients: those with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS), also known as radiographic axSpA.

  • The current average delay to diagnosis from when symptoms start is 8.5 years, by which irreversible damage to the spine may have occurred. Also, 59% of people with axial SpA (AS) report experiencing mental health problems than 25% of those with musculoskeletal conditions overall.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market

Key Benefits of Axial Spondyloarthritis (axSpA) Market Report

  • The report provides an in-depth analysis of Axial Spondyloarthritis (axSpA) Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Axial Spondyloarthritis (axSpA) Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Axial Spondyloarthritis (axSpA) current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Axial Spondyloarthritis (axSpA) market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Axial Spondyloarthritis (axSpA) Market 

The Axial Spondyloarthritis market size is anticipated to increase during the study period, owing to the increasing prevalent population of axSpA patients in the 7MM, the extensive research and development activities of pharmaceutical companies, and the expected launch of approved therapies for Axial Spondyloarthritis.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Axial Spondyloarthritis (axSpA) market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Axial Spondyloarthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Axial Spondyloarthritis (axSpA) Epidemiology

The epidemiology section covers insights about the historical and current Axial Spondyloarthritis (axSpA) patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Epidemiology Segmentation

  • Total Prevalent cases of Spondyloarthritis

  • Total Prevalent cases of Axial Spondyloarthritis

  • Age-specific cases of Axial Spondyloarthritis

  • Type-specific cases of Axial Spondyloarthritis

Axial Spondyloarthritis (axSpA) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Axial Spondyloarthritis (axSpA) market or expected to get launched in the market during the study period. The analysis covers Axial Spondyloarthritis (axSpA) market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Axial Spondyloarthritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Key companies in the Axial Spondyloarthritis market include:

  • FunPep Co Ltd

  • UCB Biopharma

  • Mycenax Biotech

  • Kinevant Sciences

  • Qyuns Therapeutics

  • Izana Bioscience

  • Clover Biopharmaceuticals

  • Suzhou Zelgen Biopharmaceuticals

And many others.

Axial Spondyloarthritis Therapies covered in the report includes:

  • FPP003

  • KIN-1901

  • QX 002N

  • Namilumab 

  • Jaktinib

  • Bimekizumab:

  • SCB-808 

  • ENIA11

And many others

Request for Sample @ Axial Spondyloarthritis (axSpA) Therapeutics Market Assessment

Table of Content

1. Key Insights

2. Executive Summary 

3. Axial Spondyloarthritis (axSpA) Competitive Intelligence Analysis

4. Axial Spondyloarthritis (axSpA) Market Overview at a Glance

5. Axial Spondyloarthritis (axSpA) Disease Background and Overview

6. Axial Spondyloarthritis (axSpA) Patient Journey

7. Axial Spondyloarthritis (axSpA) Epidemiology and Patient Population

8. Axial Spondyloarthritis (axSpA) Treatment Algorithm, Current Treatment, and Medical Practices

9. Axial Spondyloarthritis (axSpA) Unmet Needs

10. Key Endpoints of Axial Spondyloarthritis (axSpA) Treatment

11. Axial Spondyloarthritis (axSpA) Marketed Products

12. Axial Spondyloarthritis (axSpA) Emerging Therapies

13. Axial Spondyloarthritis (axSpA) Seven Major Market Analysis

14. Attribute Analysis

15. Axial Spondyloarthritis (axSpA) Market Outlook (7 major markets)

16. Axial Spondyloarthritis (axSpA) Access and Reimbursement Overview

17. KOL Views on the Axial Spondyloarthritis (axSpA) Market.

18. Axial Spondyloarthritis (axSpA) Market Drivers

19. Axial Spondyloarthritis (axSpA) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market

Healthcare Blogs by DelveInsight
Probiotics Market Size and Share Analysis
Over the past two decades, the demand for Probiotics has observed significant growth. The rising awareness about its benefits, growing popularity among the younger generation & health-conscious consumers, high expenditure power, development in new technology are the key factors actively driving the Probiotics market growth. Several key companies at the global level such as Lallemand, Danone, Nestlé, Yakult Indonesia Persada Pt, Evolve BioSystems, Inc., DuPont Healthcare, and others are diligently working in the Probiotics segment. For more details, visit: Key Companies in the Probiotics Market

Get in touch with our Business executive for Competitive Intelligence Services

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/